CA2540170C - Stabilized formulations of phosphatidylserine - Google Patents

Stabilized formulations of phosphatidylserine Download PDF

Info

Publication number
CA2540170C
CA2540170C CA2540170A CA2540170A CA2540170C CA 2540170 C CA2540170 C CA 2540170C CA 2540170 A CA2540170 A CA 2540170A CA 2540170 A CA2540170 A CA 2540170A CA 2540170 C CA2540170 C CA 2540170C
Authority
CA
Canada
Prior art keywords
phosphatidylserine
composition
matter
oil
dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2540170A
Other languages
English (en)
French (fr)
Other versions
CA2540170A1 (en
Inventor
Dorit Platt
Avidor Shulman
Gai Ben Dror
Neta Scheinman
Yoni Twito
Rassan Zuabi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Frutarom Ltd
Original Assignee
Enzymotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzymotec Ltd filed Critical Enzymotec Ltd
Publication of CA2540170A1 publication Critical patent/CA2540170A1/en
Application granted granted Critical
Publication of CA2540170C publication Critical patent/CA2540170C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/103—Extraction or purification by physical or chemical treatment of natural phosphatides; Preparation of compositions containing phosphatides of unknown structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P9/00—Preparation of organic compounds containing a metal or atom other than H, N, C, O, S or halogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA2540170A 2003-09-25 2004-09-26 Stabilized formulations of phosphatidylserine Expired - Fee Related CA2540170C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL158139 2003-09-25
IL15813903A IL158139A0 (en) 2003-09-25 2003-09-25 Stabilized formulations of phosphatidyl serine
PCT/IL2004/000895 WO2005027822A2 (en) 2003-09-25 2004-09-26 Stabilized formulations of phosphatidylserine

Publications (2)

Publication Number Publication Date
CA2540170A1 CA2540170A1 (en) 2005-03-31
CA2540170C true CA2540170C (en) 2012-02-21

Family

ID=34073789

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2540170A Expired - Fee Related CA2540170C (en) 2003-09-25 2004-09-26 Stabilized formulations of phosphatidylserine

Country Status (11)

Country Link
US (1) US8324187B2 (enExample)
EP (1) EP1663157B1 (enExample)
JP (1) JP5077841B2 (enExample)
KR (2) KR101226787B1 (enExample)
CN (1) CN1897919A (enExample)
AU (1) AU2004273700C1 (enExample)
BR (1) BRPI0414721A (enExample)
CA (1) CA2540170C (enExample)
ES (1) ES2399049T3 (enExample)
IL (2) IL158139A0 (enExample)
WO (1) WO2005027822A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935365B2 (en) * 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US8052992B2 (en) * 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
CA2611121C (en) 2005-05-31 2014-01-28 Arla Foods Amba Phosphatidylserine enriched milk fractions for the formulation of functional foods
HUE037129T2 (hu) * 2005-12-15 2018-08-28 Nestec Sa Kompozíciók és eljárások agyi funkció megõrzésére
US8877239B2 (en) * 2010-08-12 2014-11-04 Nutritional Therapeutics, Inc. Lipid supplements for maintaining health and treatment of acute and chronic disorders
DE102007042557A1 (de) 2007-09-07 2009-03-19 Membramed Gmbh Neuartige Formulierung von Phospholipiden
JP5432563B2 (ja) * 2009-03-31 2014-03-05 株式会社ファンケル ホスファチジルセリン含有カプセル及びカプセル充填用ホスファチジルセリン組成物
EP2464350B1 (en) * 2009-09-11 2016-08-24 Nestec S.A. Compositions and methods for enhancing cognitive and related functions in animals
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
WO2012143860A1 (en) * 2011-04-18 2012-10-26 Jian Guan Ameliorating cognitive decline
CN102908336B (zh) * 2011-08-05 2015-10-28 深圳市华正实业有限公司 磷脂酰丝氨酸的稳定制剂、其制备方法、应用和应用产物
ITPD20120021A1 (it) 2012-01-26 2013-07-27 Fidia Farmaceutici "nuove composizioni farmaceutiche contenenti fosfatidilserina e curcumina".
ITMI20121784A1 (it) * 2012-10-22 2014-04-23 Velleja Res Srl Composizioni galattogeniche a base di fosfatidilserina
US9101580B2 (en) * 2012-12-18 2015-08-11 Matthew Bennett Compositions and methods for treating traumatic brain injury
DK2769725T3 (en) * 2013-02-22 2016-08-22 Lipogen Ltd PREPARATIONS FOR USE AT relief of symptoms associated with premenstrual syndrome and premenstrual dysphoric disorder
EP3171706B2 (en) * 2014-07-25 2024-10-16 Frutarom Limited Nutritional compositions containing phosphatidylserine powder
CN104327114A (zh) * 2014-11-06 2015-02-04 江南大学 一种磷脂酰丝氨酸的制备方法
WO2017125816A1 (en) * 2016-01-21 2017-07-27 Enzymotec Ltd. Methods using phosphatidylserine powder
CN110283803B (zh) * 2016-06-02 2021-08-03 天津科技大学 一种磷脂酶d及其制备磷脂酸、磷脂酰丝氨酸的方法
CN107125752B (zh) * 2017-06-14 2020-06-30 安徽省芬格欣生物药业有限公司 一种增进记忆功能的磷脂酰丝氨酸口服液及制备方法
CN107034248A (zh) * 2017-06-19 2017-08-11 成都新柯力化工科技有限公司 一种连续高效酶转化合成食品用磷脂酰丝氨酸的方法
CN107722051B (zh) * 2017-08-24 2020-08-14 南通励成生物工程有限公司 制备磷脂酰丝氨酸盐的方法
GB201821049D0 (en) * 2018-12-21 2019-02-06 Ge Healthcare As Ultrasound contrast agent and methods for use therof
US20220249455A1 (en) * 2019-07-15 2022-08-11 R.P. Scherer Technologies, Llc Enteric proton pump inhibitor softgel capsule
CN110938090A (zh) * 2019-12-24 2020-03-31 南通励成生物工程有限公司 一种磷脂酰丝氨酸的纯化方法
CN112314949A (zh) * 2020-11-04 2021-02-05 上海欧睿生物科技有限公司 一种磷脂酰丝氨酸液体配制方法
KR102754261B1 (ko) * 2022-05-12 2025-01-10 주식회사 한국인삼공사 붕해성이 개선된 포스파티딜세린 함유 연질캡슐
WO2026014835A1 (ko) * 2024-07-12 2026-01-15 주식회사 아스트로젠 L-세린의 리포좀 제형 및 이의 제조 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3357918A (en) * 1964-05-27 1967-12-12 Central Soya Co Fluidized lecithin composition and method
US5015483A (en) * 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5700668A (en) * 1995-12-08 1997-12-23 Italfarmaco Sud S.P.A. Process for the industrial preparation of phosphatidylserine
IL129086A0 (en) 1999-03-22 2000-02-17 Enzymotec Ltd Surfactant-lipase complex immobilized on insoluble matrix
JP2002528507A (ja) * 1998-10-30 2002-09-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 神経疾患および病態心理学的疾患の治療および予防用の組成物
DE19917249C2 (de) 1999-02-26 2001-09-27 Meyer Lucas Gmbh & Co Verfahren zur Herstellung von Phosphatidylserin-Produkten
US6323060B1 (en) * 1999-05-05 2001-11-27 Dense-Pac Microsystems, Inc. Stackable flex circuit IC package and method of making same
JP4306899B2 (ja) * 1999-10-26 2009-08-05 株式会社ヤクルト本社 ホスファチジルセリン含有油溶組成物の製造法
AU2001259295A1 (en) * 2000-04-28 2001-11-12 Zengen, Inc. Method and composition for rapid delivery of bioactive compounds to the systemiccirculation via the nasal membrane
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
JP2001354680A (ja) * 2000-06-08 2001-12-25 Nof Corp 高安定性酸性リン脂質および製造方法
IT1319679B1 (it) * 2000-12-05 2003-10-23 Chemi Spa Processo di purificazione di fosfatidilserina.
JP4009066B2 (ja) * 2001-02-15 2007-11-14 株式会社ヤクルト本社 ホスファチジルセリンの分画法
AU2002338230A1 (en) * 2001-03-26 2002-10-15 Giventis Gmbh Food item for increasing cognitive capacity
JP4599604B2 (ja) 2002-04-19 2010-12-15 カーギル テクスチュアライジング ソリューションズ ドイチュラント ゲゼルシャフト ミット ベシュレクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 生体活性のリン脂質含有成分を含有するマトリックス
CN1306736C (zh) 2003-06-13 2007-03-21 松下电器产业株式会社 用于射频光学传输的系统和方法
US20050130937A1 (en) * 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) * 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
EP1898722B1 (en) * 2005-04-28 2013-04-10 Enzymotec Ltd. Polar lipid mixtures, their preparation and uses

Also Published As

Publication number Publication date
KR101226787B1 (ko) 2013-01-25
KR20060123100A (ko) 2006-12-01
AU2004273700C1 (en) 2010-03-11
US8324187B2 (en) 2012-12-04
ES2399049T3 (es) 2013-03-25
KR20120039752A (ko) 2012-04-25
EP1663157B1 (en) 2012-11-28
HK1092703A1 (en) 2007-02-16
AU2004273700A1 (en) 2005-03-31
WO2005027822A3 (en) 2005-10-06
JP2007506733A (ja) 2007-03-22
AU2004273700B2 (en) 2009-10-29
JP5077841B2 (ja) 2012-11-21
CN102160651A (zh) 2011-08-24
CN1897919A (zh) 2007-01-17
BRPI0414721A (pt) 2006-11-21
US20070160659A1 (en) 2007-07-12
CA2540170A1 (en) 2005-03-31
IL158139A0 (en) 2004-09-27
IL174420A0 (en) 2006-08-01
WO2005027822A2 (en) 2005-03-31
EP1663157A2 (en) 2006-06-07
EP1663157A4 (en) 2010-02-24
IL174420A (en) 2015-02-26

Similar Documents

Publication Publication Date Title
AU2004273700C1 (en) Stabilized formulations of phosphatidylserine
EP1419768B1 (en) Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction
JP2007506733A5 (enExample)
CA2352528C (en) Phosphatidyl-l-serine and phosphatidic acid composition as anti-depressant, stress suppressor and mood improver
JPWO2008062559A1 (ja) 栄養補助食品、抗疲労作用剤又は持久力増強剤、機能性食品又は化粧料
CA2213151C (en) Method of stabilizing pharmaceutical preparations comprising digestive enzyme mixtures
CA2512133C (en) Compositions of arachidonic acid for preventing or alleviating symptoms or diseases due to aging of blood vessels
EP1231213B1 (en) Procedure for the preparation of pure phosphatides and their use in the cosmetic, pharmaceutical and alimentary fields
ES2328014T3 (es) Procedimiento para la produccion de fosfolipidos.
HK1092703B (en) Stabilized formulations of phosphatidylserine
JP2001186898A (ja) 多価不飽和脂肪酸残基をもつホスファチジルセリンの製造法
CN102160651B (zh) 稳定的磷脂酰丝氨酸制剂
AU2007205762B2 (en) Process for the production of phospholipids
JPH06228170A (ja) ホスファチジルクロマノール誘導体、その製造方法、抗酸化剤及び乳化剤
BRPI0414721B1 (pt) Dispersão estável de fosfatidilserina (PS) em uma base oleosa, composição farmacêutica e cápsula
JP5041790B2 (ja) 多価不飽和脂肪酸を構成要素とするホスファチジルセリンの製造方法
JPWO2007063886A1 (ja) 多価不飽和脂肪酸含有リン脂質の製造方法及び該製造方法により得られる多価不飽和脂肪酸含有リン脂質
JPH0867635A (ja) 赤血球変形能向上剤
HK1005224B (en) Use of complex lipide as stabilizing additives in pharmaceutical formulation of digestive enzyme mixture

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210927